Tags

Type your tag names separated by a space and hit enter

[Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder].
J Fr Ophtalmol. 2020 Jul 03 [Online ahead of print]JF

Abstract

INTRODUCTION

Neuromyelitis optica spectrum disorder (NMO-SD) has been recognized for the past decade. Biomarkers such as anti-Aquaporin 4 antibodies (AQP4) and anti-Myelin Oligodendrocyte Glycoprotein (MOG) have been able to classify NMO-SD into several groups.

METHODS

A retrospective study was performed in the Strasbourg University Medical Center among patients with AQP4+, MOG+ and double-seronegative NMO to compare their clinical, epidemiological and paraclinical features.

RESULTS

Thirty-two patients with NMO were included. The AQP4+ NMO patients had a median of age of 45 years, with associated myelitis in 62.5% of cases and other autoantibodies in 37.5% of cases. The mean number of relapses by clinical history was 3. The mean initial visual acuity during an exacerbation was 0.3 LogMAR, and the visual acuity after an exacerbation was 0.1 LogMAR. MOG+NMO patients had a median age of 23 years, with severely impaired initial visual acuity (0.6 LogMAR) but better recovery (0 LogMAR); optic disc edema was present in 80% of cases; the mean number of relapses on clinical history was 1. AQP4-/MOG- NMO's were more common in women (70%) and were bilateral in 40% of cases.

CONCLUSION

The diagnostic characteristics of NMO-SD are becoming increasingly differentiated, with a positive impact on functional prognosis and long-term progression. Other biomarkers have yet to be identified to improve the diagnosis and treatment of these disorders.

Authors+Show Affiliations

Service d'ophtalmologie, Nouvel Hôpital Civil, hôpitaux universitaires de Strasbourg, BP 426, 67091 Strasbourg, France. Electronic address: delphine.osswald@chru-strasbourg.fr.Service de neurologie, hôpital de Hautepierre, hôpitaux universitaires de Strasbourg, Strasbourg, France.Service de neurologie, hôpital de Hautepierre, hôpitaux universitaires de Strasbourg, Strasbourg, France.Service d'ophtalmologie, Nouvel Hôpital Civil, hôpitaux universitaires de Strasbourg, BP 426, 67091 Strasbourg, France.

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

32631694

Citation

Osswald, D, et al. "[Clinical and Epidemiological Features in Neuromyelitis Optica Spectrum Disorder]." Journal Francais D'ophtalmologie, 2020.
Osswald D, De Seze J, Collongues N, et al. [Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder]. J Fr Ophtalmol. 2020.
Osswald, D., De Seze, J., Collongues, N., & Speeg-Schatz, C. (2020). [Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder]. Journal Francais D'ophtalmologie. https://doi.org/10.1016/j.jfo.2019.11.011
Osswald D, et al. [Clinical and Epidemiological Features in Neuromyelitis Optica Spectrum Disorder]. J Fr Ophtalmol. 2020 Jul 3; PubMed PMID: 32631694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder]. AU - Osswald,D, AU - De Seze,J, AU - Collongues,N, AU - Speeg-Schatz,C, Y1 - 2020/07/03/ PY - 2019/08/29/received PY - 2019/10/16/revised PY - 2019/11/06/accepted PY - 2020/7/8/entrez KW - Anti-Myelin Oligodendrocyte Glycoprotein (MOG) antibodies KW - Anti-aquaporin 4 (AQP4) antibodies KW - Anticorps anti-Myelin Oligodendrocyte Glycoprotein (MOG) KW - Anticorps anti-aquaporines 4 (AQP4) KW - NMO-SD KW - Neuro-ophtalmologie KW - Neuro-ophthalmology KW - Neuromyelitis optica KW - Neuromyélite optique JF - Journal francais d'ophtalmologie JO - J Fr Ophtalmol N2 - INTRODUCTION: Neuromyelitis optica spectrum disorder (NMO-SD) has been recognized for the past decade. Biomarkers such as anti-Aquaporin 4 antibodies (AQP4) and anti-Myelin Oligodendrocyte Glycoprotein (MOG) have been able to classify NMO-SD into several groups. METHODS: A retrospective study was performed in the Strasbourg University Medical Center among patients with AQP4+, MOG+ and double-seronegative NMO to compare their clinical, epidemiological and paraclinical features. RESULTS: Thirty-two patients with NMO were included. The AQP4+ NMO patients had a median of age of 45 years, with associated myelitis in 62.5% of cases and other autoantibodies in 37.5% of cases. The mean number of relapses by clinical history was 3. The mean initial visual acuity during an exacerbation was 0.3 LogMAR, and the visual acuity after an exacerbation was 0.1 LogMAR. MOG+NMO patients had a median age of 23 years, with severely impaired initial visual acuity (0.6 LogMAR) but better recovery (0 LogMAR); optic disc edema was present in 80% of cases; the mean number of relapses on clinical history was 1. AQP4-/MOG- NMO's were more common in women (70%) and were bilateral in 40% of cases. CONCLUSION: The diagnostic characteristics of NMO-SD are becoming increasingly differentiated, with a positive impact on functional prognosis and long-term progression. Other biomarkers have yet to be identified to improve the diagnosis and treatment of these disorders. SN - 1773-0597 UR - https://www.unboundmedicine.com/medline/citation/32631694/[Clinical_and_epidemiological_features_in_Neuromyelitis_Optica_Spectrum_Disorder] L2 - https://linkinghub.elsevier.com/retrieve/pii/S0181-5512(20)30245-X DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.